Pharmaceutical concern Novo Nordisk A/S (NYSE:NVO) is up 4.9% at $86.63 at last glance. The company posted strong fourth-quarter results and better-than-expected full-year revenue for 2024, as weight-loss drugs Wegovy and Ozempic reeled in billions, though sales are expected to slow this year amid supply shortages. CEO Lars Fruergaard Jorgensen also spoke to journalists after the report, saying the Danish drugmaker is well-positioned to deal with potential tariffs by the U.S. On the charts, today's pop has ...